Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Iradimed (IRMD) Long-Term Debt Repayments (2013 - 2014)

Iradimed (IRMD) reported Long-Term Debt Repayments of $6333.0 for Q1 2014, down 97.88% on a QoQ basis from $299130.0 in Q4 2013.

Iradimed (IRMD) has 2 years of Long-Term Debt Repayments data on file, last reported at $6333.0 in Q1 2014.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $6333.0 in Q1 2014, while the trailing twelve-month figure through Dec 2014 was $6333.0 (changed N/A YoY) and the FY2014 annual result came in at $6333.0, down 98.77% from the prior year.
  • Long-Term Debt Repayments retreated to $6333.0 in Q1 2014 per IRMD's latest filing, from $299130.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $299130.0 in Q4 2013 and bottomed at $6333.0 in Q1 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Iradimed 1.17 Bn 1.11 Bn 16.81 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2014 6,333.00
Mar 31, 2014 6,333.00
Dec 31, 2013 299,130.00
Dec 31, 2013 299,130.00
Sep 30, 2013 211,525.00
Sep 30, 2013 211,525.00